Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2667132 | 0.86 | ACACB (0.40) | ACACBHPGDGRM5ALDH1A1 | |
| SCHEMBL1774358 | 0.80 | GCK (0.39) | ACACB | |
| SCHEMBL3344592 | 0.71 | HPGD (0.48) | LMNAHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL391547 | 0.71 | MEN1 (0.71) | LMNAHPGDMRGPRX4MEN1KMT2A | |
| SCHEMBL2667145 | 0.71 | GCK (0.41) | ACACB | |
| SCHEMBL645466 | 0.69 | POLB (0.53) | LMNAHPGDMEN1KMT2AGRM5 | |
| SCHEMBL183994 | 0.69 | LMNA (0.70) | LMNAHPGDMRGPRX4MEN1KMT2A | |
| SCHEMBL2074319 | 0.68 | LMNA (0.48) | NAAALMNAHPGDMRGPRX4MEN1 | |
| SCHEMBL2075065 | 0.68 | LMNA (0.48) | NAAALMNAHPGDMRGPRX4MEN1 | |
| SCHEMBL2656680 | 0.68 | LMNA (0.48) | NAAALMNAHPGDMRGPRX4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GCK, GCKR, GK | NAAA 1081/4885ACACB 1233/4885LMNA 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.